- Document Number:
20220016276
- Appl. No:
17/487801
- Application Filed:
September 28, 2021
- نبذة مختصرة :
A composition comprising catalase, a preparation method and a use thereof, and a method for killing tumor cells are provided. The composition comprises a radionuclide labeled to a biomacromolecule, a soluble alginate and catalase. The composition can be injected into the tumor through an interventional treatment. A gel is formed when an alginate ion in the composition enters the tumor and encounters a calcium ion, such that the radionuclide and the catalase are uniformly confined in the tumor. The composition comprising catalase utilizes catalase to decompose dissolved oxygen generated from hydrogen peroxide in the tumor to advance the hypoxic state of the tumor cells, and the tumor cells are killed with radiation after the hypoxic state thereof has been advanced, and thus the invention has good prospects for applications in cancer therapy.
- Claim:
1. A composition comprising catalase, comprising catalase, a soluble alginate, and a radionuclide labeled on a bio-macromolecule.
- Claim:
2. The composition according to claim 1, wherein the soluble alginate includes at least one selected from the group consisting of sodium alginate, potassium alginate, ammonium alginate and propylene glycol alginate.
- Claim:
3. The composition according to claim 2, wherein the soluble alginate includes sodium alginate and/or potassium alginate.
- Claim:
4. The composition according to claim 1, wherein the bio-macromolecule includes at least one selected from the group consisting of a protein, a nucleic acid and a polysaccharide.
- Claim:
5. The composition according to claim 1, wherein the radionuclide includes at least one selected from the group consisting of iodine-131, iodine-125, phosphorus-32, yttrium-90, gallium-67, indium-111, thallium-201, palladium-203, bismuth-213, actinium-225, lutecium-177, rhenium-186, palladium-212 and rhenium-188.
- Claim:
6. The composition according to claim 1, wherein the radionuclide is iodine-131 or iodine-125.
- Claim:
7. The composition according to claim 1, wherein the radionuclide is labeled on the catalase.
- Claim:
8. The composition according to claim 1, wherein the concentration of the catalase is 5 mg/mL-10 mg/mL, the concentration of the alginate is 5 mg/mL-10 mg/mL, and/or the dose of the radionuclide is 200 Ci/mL-500 Ci/mL.
- Claim:
9. The composition according to claim 1, wherein the composition further comprises an immune-stimulating agent.
- Claim:
10. The composition according to claim 9, wherein the immune-stimulating agent includes at least one selected from the group consisting of CpG oligodeoxynucleotide which is a immunologic adjuvant, R837, TLR7 agonists, TLR8 agonists, NLR agonists, STING agonists, MPLA (Monophosphoryl Lipid A), LPS, PGNs, R848, G100, SD-101, MGN1703, CMP-001, FLA, polyU, poly(dT), CL307, CL264, CL097, CL075, MEDI9197, MEDI5083, hypoxanthine and MDP.
- Claim:
11. A method for preparing a composition comprising catalase, comprising mixing an alginate solution, a radionuclide and a catalase.
- Claim:
12. The method for preparing a composition according to claim 11, wherein the ratio of the amount of the alginate, catalase, and radionuclide is 5 mg-10 mg: 5 mg-10 mg: 200 Ci-500 Ci.
- Claim:
13. The method for preparing a composition according to claim 11, wherein the method of mixing includes mixing an alginate solution with radionuclide-labeled catalase.
- Claim:
14. The method for preparing a composition according to claim 13, wherein the radionuclide-labeled catalase is prepared by a method comprising mixing the radionuclide with an oxidizing agent and a dispersion medium, and mixing the obtained mixture with the catalase.
- Claim:
15. The method for preparing a composition according to claim 13, wherein the radionuclide-labeled catalase is prepared by a method comprising mixing the catalase with a chelating agent, mixing the obtained mixture with the radionuclide and a reducing agent, and purifying.
- Claim:
16. The composition according to 10 claim 1 for use in the preparation of an anti-neoplastic agent.
- Claim:
17. The use of the composition for the preparation of an anti-neoplastic agent according to claim 16, wherein the composition is used in combination with at least one selected from the group consisting of an antibody against cytotoxic T-lymphocyte-associated antigen-4, anti-PD-1 and anti-PD-L1.
- Claim:
18. A method for killing tumor cells, comprising injecting the composition according to claim 1 into a tumor by means of interventional treatment, wherein a network-like cross-linked gel structure is formed according to the internal structure of the tumor when the alginate ions in the composition enter into the tumor and encounter calcium ions, and adheres to the inside of the tumor, such that the radionuclides labeled on bio-macromolecules and catalase are uniformly coated and confined within the tumor; and wherein the catalase decomposes hydrogen peroxide in the tumor to produce dissolved oxygen to relieve the hypoxia in tumor cells; and the rays generated by the radionuclides kill tumor cells in which the hypoxia has been relieved.
- Claim:
19. The method for killing tumor cells according to claim 18, wherein the calcium concentration in blood or in tumors and surrounding tissue regions is adjusted prior to the interventional treatment.
- Claim:
20. The composition according to claim 1, wherein the bio-macromolecule includes a catalase.
- Current International Class:
61; 61; 61
- الرقم المعرف:
edspap.20220016276
Processing Request
No Comments.